The pharmaceutical industry’s trade group ousted 22 companies earlier this week after it revised membership rules. The move comes as lawmakers in Washington have pressed the pharma industry about U.S. drug prices.
The updated membership rules for the Pharmaceutical Research and Manufacturers of America (PhRMA) group mandates that members spend at least $200 million each year on R&D. The rules also say that companies’ global R&D to global sales ratio must be 10% or more.
Get the full story at our sister site, Drug Delivery Business News.
The post Amid drug-pricing criticism, industry trade group ousts members appeared first on MassDevice.